12:00 AM
 | 
Feb 02, 2009
 |  BC Week In Review  |  Company News  |  Other News

Basilea infectious, dermatology news

Basilea will reduce its R&D headcount by 30 and add 100 employees to support the launch and commercialization of Toctino alitretinoin and Zeftera/ Zevtera ceftobiprole. Toctino is marketed to treat severe chronic hand eczema unresponsive to...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >